Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 317-334 , June 2009

Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients

References 

  1. Seidell JC. Obesity, insulin resistance and diabetes - a worldwide epidemic. The British Journal of Nutrition. 2000;2000:S5–S8
  2. Kopelman PG, Hitman GA. Diabetes. Exploding type II. Lancet. 1998;352(Suppl. 4):SIV5
  3. Cook S, Scherrer U. Insulin resistance, a new target for nitric oxide-delivery drugs. Fundamental & Clinical Pharmacology. 2002;16:441–453
  4. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine. 1997;14(Suppl. 5):S1–85
  5. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The American Journal of Cardiology. 2004;93:136–141
  6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  7. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. The Journal of the American Medical Association. 2003;289:76–79
  8. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the ‘Yin-Yang’ effect–a Chinese concept for a worldwide pandemic. Swiss Medical Weekly. 2006;136:103–113
  9. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine. 1998;339:229–234
  10. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal. 2000;321:405–412
  11. Group DS, on behalf of the European Diabetes Epidemiology G . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine. 2001;161:397–405
  12. Stein B, Weintraub WS, Gebhart SSP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979–989
  13. Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996;94:1818–1825
  14. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. Journal of the American College of Cardiology. 2008;52:1134–1140
  15. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. British Medical Journal. 2008;337:a1331
  16. Cook S, Meier B, Windecker S. Sirolimus-eluting versus paclitaxel-eluting stents: are there differences in reality?. The Internet Journal of Cardiology. 2007;19–25Spring
  17. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112:2175–2183
  18. Baumgart D, Klauss V, Baer F, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Journal of the American College of Cardiology. 2007;50:1627–1634
  19. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. The New England Journal of Medicine. 2007;357:1393–1402
  20. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. The New England Journal of Medicine. 2007;356:989–997
  21. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. The New England Journal of Medicine. 2007;356:1030–1039
  22. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948
  23. Carson JL, Scholz PM, Chen AY, et al. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. Journal of the American College of Cardiology. 2002;40:418–423
  24. Mohammadi S, Dagenais F, Mathieu P, et al. Long-term impact of diabetes and its comorbidities in patients undergoing isolated primary coronary artery bypass graft surgery. Circulation. 2007;116:I-220–I-225
  25. Leavitt BJ, Sheppard L, Maloney C, et al. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation. 2004;110:II-41–II-44
  26. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2,127 arterial to coronary conduits over 15 years. The Annals of Thoracic Surgery. 2004;77:93–101
  27. Stevens LM, Carrier M, Perrault LP, et al. Influence of diabetes and bilateral internal thoracic artery grafts on long-term outcome for multivessel coronary artery bypass grafting. European Journal of Cardio-Thoracic Surgery. 2005;27:281–288
  28. de Jaegere PPT, Suyker WJL. Off-pump coronary artery bypass surgery. Heart. 2002;88:313–318
  29. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. The Journal of the American Medical Association. 2005;293:1501–1508
  30. Bravata DM, Gienger AL, McDonald KM, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Annals of Internal Medicine. 2007;147:703–716
  31. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The New England Journal of Medicine. 1996;335:217–225
  32. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation. 1997;96:1761–1769
  33. Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in the bypass angioplasty revascularization investigation registry: comparison with the randomized trial. Circulation. 2000;101:2795–2802
  34. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . The final 10-year follow-up results from the BARI randomized trial. Journal of the American College of Cardiology. 2007;49:1600–1606
  35. Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised intervention treatment of angina. [see comments] Lancet. 1998;352:1419–1425
  36. King SB, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. The New England Journal of Medicine. 1994;331:1044–1050
  37. CABRI Trial Participants . First-year results of CABRI (coronary angioplasty versus bypass revascularisation investigation). Lancet. 1995;346:1179–1184
  38. Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. Journal of the American College of Cardiology. 2002;40:1555–1566
  39. Serruys PW, Ong ATL, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. Journal of the American College of Cardiology. 2005;46:575–581
  40. Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation. 2008;118:381–388
  41. Rodriguez AE, Baldi J, Pereira CF, et al. Five-year follow-up of the argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). Journal of the American College of Cardiology. 2005;46:582–588
  42. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2007;115:1082–1089
  43. Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. The Journal of Thoracic and Cardiovascular Surgery. 2005;130:512–519
  44. Serruys, P., What have we learned from ARTS I and ARTS II? AHA, special session, November 4th. 2007, AHA/ESC joint session: multivessel coronary artery disease — stents vs CABG:room W415a.
  45. Serruys PW, Colombo A, Morice MC, et al. Arterial revascularisation therapies study part II - sirolimus-eluting stents for the treatment of patients with multivessel de novocoronary artery lesions. EuroIntervention. 2005;1:147–156
  46. Rodriguez AE, Maree AO, Mieres J, et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. European Heart Journal. 2007;28:2118–2125
  47. Yang JH, Gwon H-C, Cho SJ, et al. Comparison of coronary artery bypass grafting with drug-eluting stent implantation for the treatment of multivessel coronary artery disease. The Annals of Thoracic Surgery. 2008;85:65–70
  48. Javaid A, Steinberg DH, Buch AN, et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation. 2007;116:I-200–I-206
  49. Yang ZK, Shen WF, Zhang RY, et al. Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease. Journal of Interventional Cardiology. 2007;20:10–16
  50. Briguori C, Condorelli G, Airoldi F, et al. Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. The American Journal of Cardiology. 2007;99:779–784
  51. Lee MS, Jamal F, Kedia G, et al. Comparison of bypass surgery with drug[hyphen (true graphic)]eluting stents for diabetic patients with multivessel disease. International Journal of Cardiology. 2007;123:34–42
  52. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents versus coronary-artery bypass grafting in multivessel coronary disease. The New England Journal of Medicine. 2008;358:331–341
  53. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. The New England Journal of Medicine. 2005;352:2174–2183
  54. Kapur A. Coronary artery revascularisation in diabetes. The CARDia trial. European Heart Journal. 2008;Hotlines II. Session 1694–1695: ESC, September 1
  55. Serruys, P.W.; Mohr, F.W.; investigators obotS., The Synergy between percutaneous coronary intervention with TAXUS and cardiac surgery: the SYNTAX study. New Engl J Med 359: in press.
  56. Harjai KJ, Stone GW, Boura J, et al. Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. The American Journal of Cardiology. 2003;91:1041–1045
  57. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomisned trials. Lancet. 2003;361:13–20
  58. Grines C, Patel A, Zijlstra F, et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. American Heart Journal. 2003;145:47–57
  59. Timmer JR, Ottervanger JP, Thomas K, et al. Long-term, cause-specific mortality after myocardial infarction in diabetes. European Heart Journal. 2004;25:926–931
  60. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England Journal of Medicine. 2001;344:1895–1903
  61. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. European Heart Journal. 2007;28:443–449
  62. Stuckey TD, Stone GW, Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American Journal of Cardiology. 2005;95:1–7
  63. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. [see comments] The New England Journal of Medicine. 1999;341:625–634
  64. White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the should we emergently revascularize occluded coronaries for cardiogenic shock (SHOCK) trial. Circulation. 2005;112:1992–2001
  65. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation. 2000;102:1014–1019
  66. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767–2771
  67. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II investigators. Fast revascularisation during instability in coronary artery disease. Lancet. 2000;356:9–16
  68. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology. 2004;43:585–591
  69. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIB/IIIA inhibitor tirofiban. The New England Journal of Medicine. 2001;344:1879–1887

PII: S1521-690X(08)00171-1

doi: 10.1016/j.beem.2008.12.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 317-334 , June 2009

Article Tools

* Image Usage & Resolution